Lemanska, A. and Harkin, Andrea and Iveson, T. and Kelly, Caroline and Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8 (6): 102063. ISSN 2059-7029
AI Summary:
A neuropathy assessment before treatment with oxaliplatin can help identify people with an increased risk of chemotherapy-induced peripheral neuropathy (CIPN).AI Topics:
Background:
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of oxaliplatin. CIPN can impair long-term quality of life and limit the dose of chemotherapy. We investigated the association of CIPN over time with age, sex, body mass index, baseline neuropathy, and chemotherapy regimen in people treated with adjuvant oxaliplatin-containing chemotherapy for colorectal cancer.
Patients and methods:
We carried out secondary analysis of data from the SCOT randomised controlled trial. SCOT compared 3 months to 6 months of oxaliplatin-containing adjuvant chemotherapy in 6088 people with colorectal cancer recruited between March 2008 and November 2013. Two different chemotherapy regimens were used: capecitabine with oxaliplatin (CAPOX) or fluorouracil with oxaliplatin (FOLFOX). CIPN was recorded with the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-Neurotoxicity 4 tool in 2871 participants from baseline (randomisation) for up to 8 years. Longitudinal trends in CIPN [averages with 95% confidence intervals (CIs)] were plotted stratified by the investigated factors. Analysis of covariance (ANCOVA) was used to analyse the association of factors with CIPN adjusting for the SCOT randomisation arm and oxaliplatin dose. P < 0.01 was adopted as cut-off for statistical significance to account for multiple testing.
Results:
Patients receiving CAPOX had lower CIPN scores than those receiving FOLFOX. Chemotherapy regimen was associated with CIPN from 6 months (P < 0.001) to 2 years (P = 0.001). The adjusted ANCOVA coefficient for CAPOX at 6 months was −1.6 (95% CIs −2.2 to −0.9) and at 2 years it was −1.6 (95% CIs −2.5 to −0.7). People with baseline neuropathy scores ≥1 experienced higher CIPN than people with baseline neuropathy scores of 0 (P < 0.01 for all timepoints apart from 18 months). Age, sex, and body mass index did not link with CIPN.
Conclusions:
A neuropathy assessment before treatment with oxaliplatin can help identify people with an increased risk of CIPN. More research is needed to understand the CIPN-inducing effect of different chemotherapy regimens.
Lemanska, A.
Author
Lemanska, A. and Harkin, Andrea and Iveson, T. and Kelly, Caroline and Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8 (6): 102063. ISSN 2059-7029
See full publications listHarkin, Andrea
Author
Pennel, Kathryn A.F. and Hatthakarnkul, Phimmada and Wood, Colin S. and Lian, Guang-Yu and Al-Badran, Sara and Quinn, Jean A. and Legrini, Assya and Inthagard, Jitwadee and Alexander, Peter G. and van Wyk, Hester and Kurniawan, Ahmad and Hashmi, Umar and Gillespie, Michael A. and Mills, Megan and Ammar, Aula and Hay, Jennifer and Andersen, Ditte and Nixon, Colin and Rebus, Selma and Chang, David K. and Kelly, Caroline and Harkin, Andrea and Graham, Janet and Church, David and Tomlinson, Ian and Saunders, Mark and Iveson, Tim and Lannagan, Tamsin R. M. and Jackstadt, Rene and Maka, Noori and Horgan, Paul G. and Roxburgh, Campbell S. D. and Sansom, Owen J. and McMillan, Donald C. and Steele, Colin W. and Jamieson, Nigel B. and Park, James H. and Roseweir, Antonia K. and Edwards, Joanne (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43: 64. ISSN 1756-9966
Lemanska, A. and Harkin, Andrea and Iveson, T. and Kelly, Caroline and Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8 (6): 102063. ISSN 2059-7029
Frei, Anja L. and McGuigan, Anthony and Sinha, Ritik RAK and Glaire, Mark A. and Jabbar, Faiz and Gneo, Luciana and Tomasevic, Tijana and Harkin, Andrea and Iveson, Tim J. and Saunders, Mark and Oein, Karin and Maka, Noori and Pezella, Francesco and Campo, Leticia and Hay, Jennifer and Edwards, Joanne and Sansom, Owen J. and Kelly, Caroline and Tomlinson, Ian and Kildal, Wanja and Kerr, Rachel S. and Kerr, David J. and Danielsen, Håvard E. and Domingo, Enric and Church, David N. and Koelzer, Viktor H. (2023) Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. Journal of Pathology: Clinical Research, 9 (6). pp. 449-463. ISSN 2056-4538
See full publications listIveson, T.
Author
Lemanska, A. and Harkin, Andrea and Iveson, T. and Kelly, Caroline and Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8 (6): 102063. ISSN 2059-7029
See full publications listKelly, Caroline
Author
Derby, Sarah and Jackson, Mark R. and Williams, Karin and Stobo, Jamie and Kelly, Caroline and Sweeting, Lorna and Shad, Shumaila and Herbert, Christopher and Short, Susan C. and Williamson, Aoife and James, Allan and Nowicki, Stefan and Bulbeck, Helen and Chalmers, Anthony (2024) Concurrent olaparib and radiotherapy in elderly patients with newly diagnosed glioblastoma: the phase I dose escalation PARADIGM trial. International Journal of Radiation Oncology, Biology, Physics, 118 (5). pp. 1371-1378. ISSN 0360-3016
Pennel, Kathryn A.F. and Hatthakarnkul, Phimmada and Wood, Colin S. and Lian, Guang-Yu and Al-Badran, Sara and Quinn, Jean A. and Legrini, Assya and Inthagard, Jitwadee and Alexander, Peter G. and van Wyk, Hester and Kurniawan, Ahmad and Hashmi, Umar and Gillespie, Michael A. and Mills, Megan and Ammar, Aula and Hay, Jennifer and Andersen, Ditte and Nixon, Colin and Rebus, Selma and Chang, David K. and Kelly, Caroline and Harkin, Andrea and Graham, Janet and Church, David and Tomlinson, Ian and Saunders, Mark and Iveson, Tim and Lannagan, Tamsin R. M. and Jackstadt, Rene and Maka, Noori and Horgan, Paul G. and Roxburgh, Campbell S. D. and Sansom, Owen J. and McMillan, Donald C. and Steele, Colin W. and Jamieson, Nigel B. and Park, James H. and Roseweir, Antonia K. and Edwards, Joanne (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43: 64. ISSN 1756-9966
Frei, Anja L. and McGuigan, Anthony and Sinha, Ritik R.A.K. and Jabbar, Faiz and Gneo, Luciana and Tomasevic, Tijana and Iveson, Tim and Saunders, Mark P. and Oien, Karin A. and Maka, Noori and Pezzella, Francesco and Campo, Leticia and Browne, Molly and Glaire, Mark and Kildal, Wanja and Danielsen, Havard E. and Hay, Jennifer and Edwards, Joanne and Sansom, Owen and Kelly, Caroline and Tomlinson, Ian and Kerr, Rachel and Kerr, David and Domingo, Enric and TransSCOT consortium and Church, David N. and Koelze, Viktor H. (2024) Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: A retrospective analysis. Lancet Oncology, 25 (2). pp. 198-211. ISSN 1470-2045
See full publications listSaunders, M.
Author
Lemanska, A. and Harkin, Andrea and Iveson, T. and Kelly, Caroline and Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8 (6): 102063. ISSN 2059-7029
See full publications listFaithfull, S.
Author
Lemanska, A. and Harkin, Andrea and Iveson, T. and Kelly, Caroline and Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8 (6): 102063. ISSN 2059-7029
See full publications listAvailable under License Creative Commons Attribution.
Download (459kB) | Preview
 |